Business
Avivagen Announces Positive Results from New Zealand OxC-betaTM Livestock Dairy Trial for Use Against Sub-Clinical Mastitis
Avivagen Announces Positive Results from New Zealand OxC-betaTM Livestock Dairy Trial for Use Against Sub-Clinical Mastitis.
About this update from Avivagen, Inc.
[{"type":"text","content":"Avivagen Inc. (TSXV:VIV) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that enhance feed intake and safely support immune function, thereby supporting general health and performance, is pleased to announce positive and statistically significant results from its recently completed New Zealand dairy trial that demonstrated OxC-beta™ Livestock’s contribution against sub-clinical mastitis.Mastitis is one of the costliest diseases for treatment in the dairy industry, as animals infected with mastitis must be treated by antibiotics, requiring that the infected dairy cows be removed from milk production until fully healthy in order to ensure that their milk does not contain antibiotics.“We have assessed a number of compounds in terms of their ability to help clear sub clinical mastitis, and this is the first time we have seen a positive effect.”” said Scott McDougall, BSc(Vet), BVSc, PhD; Managing Director of Cognsoco.“In the United States alone mastitis costs dairy producers more than $2 billion in lost production each year, due in large part to the use of product-contaminating antibiotics for treatment. A non-antibiotic solution that targets the cow’s own immune system as a strategy for preventing and treating of subclinical mastitis has the real-world potential to save billions annually for the global dairy industry1,” says Kym Anthony, Chief Executive Officer of Avivagen. “We are extremely excited that these results show OxC-betaTM Livestock is a viable and safe alternative for dairy producers in high quality markets like New Zealand and others around the world. This is an important new application of OxC-betaTM Livestock that can promote both improved physical health in dairy cows and improved financial health for producers worldwide.”The trial was conducted over 42 days at four commercial dairy farms on the North Island of New Zealand by Cognosco, a veterinary services and research group working closely with the New Zealand dairy industry. Highlights from this trial, which began in September 2019, include:Cows were enrolled in the study based on test results confirming the presence of subclinical mastitis.The dairy cows enrolled presented a somatic cell count in milk of at least 200,000 cells/mL and a positive test for the ...